Tesamorelin: Mechanism, Safety, and Uses
Tesamorelin: Mechanism, Safety, and Uses
The content on this page is for general informational and educational purposes only and is not intended as medical advice, a recommendation, or an endorsement of any specific medication, treatment, or health product. Always consult a qualified healthcare provider before making decisions about medications, supplements, or changes to your health regimen. BodySpec does not prescribe, dispense, promote, offer, sell, or facilitate access to any of the pharmaceutical products discussed below.
Deep abdominal fat can stubbornly resist diet and exercise, posing a unique challenge for people with HIV-associated lipodystrophy.
Tesamorelin is a synthetic analog of human growth hormone–releasing hormone. Approved by the FDA in 2010 to target excess visceral adipose tissue in adults with HIV-associated lipodystrophy, it mobilizes deep fat stores while supporting lean mass preservation (Mayo Clinic, 2024).
Mimicking the body’s natural GHRH signals, tesamorelin engages pituitary receptors to reshape deep visceral fat compartments (distinct from subcutaneous fat) and influence metabolic health.
Mechanism of Action
Tesamorelin’s peptide structure interacts with growth hormone–releasing hormone (GHRH) receptors in the pituitary gland. It then:
- Stimulates pulsatile release of growth hormone, promoting lipolysis in deep visceral fat (Cleveland Clinic, 2025).
- Raises insulin-like growth factor 1 (IGF-1) levels, which help maintain lean mass (DailyMed, 2025).
Who Uses Tesamorelin and How It’s Given
Clinicians prescribe tesamorelin to reduce excess visceral fat in adults with HIV-associated lipodystrophy. It’s administered via daily subcutaneous injection; consult the official prescribing information for handling and dosing details.
What the Research Shows
In a 26-week, placebo-controlled study, participants receiving tesamorelin experienced a mean 10.9% reduction in visceral adipose tissue compared to 0.6% in the placebo group (Falutz et al., 2010).
| Outcome | Tesamorelin Group | Placebo Group |
|---|---|---|
| Mean change in VAT at 26 weeks | −10.9% | −0.6% |
Safety and Monitoring
Patients should discuss potential side effects and monitoring plans with their healthcare provider.
Common Side Effects
- Injection site redness or discomfort (MedlinePlus, 2024).
- Joint aches.
- Peripheral swelling.
- Headache.
Serious Considerations
- Potential glucose intolerance; monitor fasting glucose and HbA1c regularly.
- Rare hypersensitivity reactions.
Recommended Checks
- Baseline and periodic IGF-1 levels.
- Routine fasting glucose and HbA1c.
- Liver function tests.
Research-Grade Specifications
Tesamorelin’s molecular profile:
- CAS number: 218949-48-5.
- Molecular weight: 5,135.9 Da.
- Sequence length: 44 amino acids (DrugBank, 2026).
For context on body composition components, see What Is Body Composition.
Comparing GHRH Analogs
| Peptide | FDA Status | Typical Use | Half-life |
|---|---|---|---|
| Tesamorelin | Approved for HIV lipodystrophy | Visceral fat reduction | ~26–38 minutes (DrugBank, 2026) |
| Sermorelin | Not approved for lipodystrophy | GH deficiency evaluation | ~11 minutes (DrugBank, 2026) |
| CJC-1295 with DAC | Research use only | Experimental GH stimulation | ~6–8 days (Mavrych et al., 2026) |
Conclusion
Tesamorelin is a clinically validated therapy for reducing visceral adipose tissue while supporting lean mass in adults with HIV-associated lipodystrophy.
Because shifts in visceral and subcutaneous fat can affect metabolic health, objective measurement matters. DEXA scans provide precise data on fat compartments, lean tissue, and bone density. To explore lean mass benchmarks, see our Lean Mass Index guide. For insights on bone density alongside body composition, read Benefits of a DEXA Scan for Bone, Fat, and Muscle Analysis. To track these changes over time, use our tool to find a BodySpec DEXA scan near you.
